
WilmerHale Counsels Tokai Pharmaceuticals in Share Purchase Agreement with Otic Pharma

DECEMBER 28, 2016

Tokai Pharmaceuticals Inc. and Otic Pharma Ltd., a privately held, clinical-stage pharmaceutical company focusing on the development and commercialization of products for disorders of the ear, nose and throat, announced that the two companies—together with the shareholders of Otic Pharma—have entered into a definitive share purchase agreement under which the shareholders of Otic Pharma will become the majority owners of Tokai.

The WilmerHale deal team included Partners [Hal Leibowitz](#), [Stuart Falber](#), [Belinda Juran](#), [Bill Caporizzo](#) and [Amy Null](#); Counsel [Michael Welhouse](#); Senior Associate [Ryan Mitteness](#); and Associate [Andrea Sorrentino](#).

Read Tokai Pharmaceuticals' [press release](#) for more information.